In one paragraphReview in Neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
36 authors.
Chelsea KotchDepartment of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.ORCID 0000-0001-6561-575X Sebastien PerreaultDivision of Child Neurology, Department of Neurosciences, Université de Montréal, Montréal, QC, Canada.ORCID 0000-0002-4417-7698 Phoebe PowerDepartment of Pediatric Oncology, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts, USA.ORCID 0009-0002-2333-4428 Kenneth AldapeLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.ORCID 0000-0001-5119-7550 Robert A AveryDivision of Ophthalmology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.ORCID 0000-0003-1453-7282 Pratiti BandopadhayayDepartment of Pediatric Oncology, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts, USA.ORCID 0000-0002-4175-4760 David CapperDepartment of Neuropathology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität Zu Berlin, Berlin, Germany.ORCID 0000-0003-1945-497X Peter de BlankDepartment of Pediatrics, University of Cincinnati College of Medicine and Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.ORCID 0000-0001-6623-3040 Natacha Entz-WerlePediatric Oncology Department, University Hospitals of Strasbourg, Strasbourg, France.ORCID 0000-0001-8418-7439 Jordan R HansfordMichael Rice Centre for Hematology and Oncology, Women's and Children's Hospital, Adelaide University, Adelaide, South Australia, Australia.ORCID 0000-0001-7733-383X Cynthia HawkinsArthur and Sonia Labatt Brain Tumour Research Centre, SickKids Research Institute, Toronto, Ontario, Canada.ORCID 0000-0003-2618-4402 Thomas S JacquesDepartment of Histopathology, Great Ormond Street Hospital for Children, UCL GOS Institute of Child Health, London, UK.ORCID 0000-0002-7833-2158 David T W JonesGerman Cancer Research Center (DKFZ), Hopp Children's Cancer Center Heidelberg (KiTZ) and Division of Pediatric Glioma Research (B360), Heidelberg, Germany.ORCID 0000-0002-2036-5141 Benjamin H KannDepartment of Radiation Oncology, Brigham and Women's Hospital, Boston, Massachusetts, USA.ORCID 0000-0002-4313-2754 Adrian LevineArthur and Sonia Labatt Brain Tumour Research Centre, SickKids Research Institute, Toronto, Ontario, Canada.ORCID 0000-0003-1048-3360 Juan Pedro Martinez-BarberaDevelopmental Biology and Cancer, UCL GOS Institute of Child Health, London, UK.ORCID 0000-0002-5292-7276 Till MildeGerman Cancer Research Center (DKFZ), Hopp Children's Cancer Center Heidelberg (KiTZ) and Division of Pediatric Glioma Research (B360), Heidelberg, Germany.ORCID 0000-0002-7267-1052 Sabine MuellerDepartment of Neurology and Pediatrics, University of California San Francisco, San Francisco, California, USA.ORCID 0000-0002-3452-5150 Jean M Mulcahy LevyMorgan Adams Foundation Brain Tumor Research Program, Department of Pediatrics, Children's Hospital Colorado, Aurora, Colorado, USA.
Yoshiko NakanoArthur and Sonia Labatt Brain Tumour Research Centre, SickKids Research Institute, Toronto, Ontario, Canada.ORCID 0000-0001-5394-8194 Roger J PackerBrain Tumor Institute and Gilbert Family Neurofibromatosis Institute, Children's National Hospital, Washington, District of Columbia, USA.
Stefan PfisterGerman Cancer Research Center (DKFZ), Hopp Children's Cancer Center Heidelberg (KiTZ) and Division of Pediatric Glioma Research (B360), Heidelberg, Germany.ORCID 0000-0002-5447-5322 Eric RaabeDivision of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.ORCID 0000-0002-9368-7037 Nathan J RobisonCancer and Blood Disease Institute, Children's Hospital Los Angeles, Los Angeles, California, USA.ORCID 0000-0001-8613-9772 Uri TaboriArthur and Sonia Labatt Brain Tumour Research Centre, SickKids Research Institute, Toronto, Ontario, Canada.ORCID 0000-0002-5019-2683 Kee Kiat YeoDepartment of Pediatric Oncology, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts, USA.ORCID 0000-0003-0713-6384 Yuan ZhuDepartment of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas, USA.ORCID 0000-0002-6173-0627 Michael J FisherDepartment of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.ORCID 0000-0003-3753-3700 Darren HargraveDepartment of Hematology and Oncology, University College London Great Ormond Street Institute of Child Health, London, UK (D.H.).ORCID 0000-0001-8219-9807 Lindsay B KilburnDivision of Oncology, Children's National Hospital, Washington, District of Columbia, USA.
Funding
Neurofibromatosis Therapeutic Acceleration Program 1054237NIHR GOSH BRC
6 · The paper itselfAbstract
The clinical trial landscape of molecularly targeted treatments for pediatric low-grade glioma (pLGG) has created an exciting and hopeful era for both patients and clinicians alike. Despite numerous clinical trials investigating the use of targeted agents for pLGG, only two oral precision-based regimens for pLGG have received federal agency approval. However, enthusiasm surrounding recently completed early phase clinical trials has resulted in increased off-label prescribing practices beyond the federally-approved indications, despite a lack of phase 3 clinical trial data and an incomplete understanding of the long-term radiographic, functional outcomes, and toxicity for both approved and experimental therapies. These gaps in knowledge are critically important to consider when selecting therapies for patients with pLGG, as the prevention and reduction of late effects in pLGG survivors is crucial to prevent long-term morbidity. In this editorial by the clinical working group of the International pLGG Coalition, we discuss the landscape of molecularly targeted therapies for pLGG, outline the unanswered questions for the use of novel therapies in the management of pLGG, review the risks and benefits of early off-label use of targeted agents, and discuss the importance of patience and evidence-based clinical practice in the rapidly evolving era of precision medicine.
Indexed as
Brain NeoplasmsGliomaMolecular Targeted TherapyPrecision MedicineChildHumans
Identifiers
PMID42155029
PMCPMC13550684
What OpenQuestion holds
Textmetadata
Read underepoch 390